Branded vs Generic Drugs in Russia and CEE – Expert Insights

Date: July 22, 2010
Pages: 43
Price:
US$ 395.00
Publisher: FirstWord
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B96A30A4B34EN
Leaflet:

Download PDF Leaflet

Branded vs Generic Drugs in Russia and CEE – Expert Insights
Across Russia and former Communist countries in Central and Eastern Europe, the battle for market share is being played out on three fronts between patented drugs, branded and commodity generics.

And it’s not surprising. While consumers prefer the status of innovative patented drugs produced by recognizable Western pharma giants, they are culturally attached to inexpensive, government-subsidized products. And as more and more patented blockbusters go off-patent, branded generics and commodity products alike have gained ground.

Yet the barriers to winning the hearts and wallets of consumers in the region are considerable. Government reimbursement schemes encourage the use of commodity generic brands, which are four times less expensive than patented medications. Legal issues abound, too. Competition between branded and commodity drugs often leads to intellectual property court battles and patent disputes. And in a region well-supported by generics companies, innovative drug brands are often priced out of competition.

Even so, many experts believe that despite the crowded market, there is still room for new entrants in many categories. In Branded vs Generic Drugs in Russia and CEE – expert insights, FirstWord assesses the pharma landscape in CEE countries, including Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Russia and Slovakia. The report offers an historical perspective cast against economics, cultural preferences and most importantly, the current market climate. Featuring case studies, key insights and interview transcripts with pharmaceutical leaders in the region, the report defines the scope of pharma’s challenges in the region.

The report offers insights into:
  • The current climate market, broken down by branded and generic sectors
  • How innovative pharmaceutical companies can make inroads into the region

The report
  • Offers an historical, cultural and economic breakdown of the region
  • Reviews which companies are gaining headway, and why
  • Includes full transcripts of interviews with key pharmaceutical executives
  • Offers case studies from leading companies including Pfizer and Gedeon Richter

SOME OF THE KEY COMPANIES ANALYZED IN THIS REPORT

GlaxoSmithKline
AstraZeneca
Merck
Teva
Gedeon Richter
Sopharma
Chaikapharma
Biovet
INTRODUCTION

Purpose of the report
Geographical coverage
Executive summary

MARKET OVERVIEW

Key branded drug manufacturers
Key generics manufacturers
Historical perspective—recent material trends and changes
Economic perspective—regulatory, re-imbursement and other business factors
Cultural perspective—regional culture as a key factor
Current market position of branded versus generics

KEY INSIGHTS

Selected case studies
  Pfizer
  Gedeon Richter
Valenta
  Novartis Consumer Health
  Polfa Warsaw
  Novartis Slovakia
  Top ten pharmaceutical company in Poland

KEY FINDINGS

CONCLUSIONS

INDEX
Skip to top


Branded vs Generics Drugs in Latin America US$ 395.00 Feb, 2010 · 52 pages
Generic Drugs in Consumer Health Global Overview 2011 US$ 2,000.00 Jul, 2011 · 50 pages
Russia Beer Market Insights Report 2015 US$ 10,792.00 Aug, 2015 · 170 pages

Ask Your Question

Branded vs Generic Drugs in Russia and CEE – Expert Insights
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: